Taking Action Sample Clauses

Taking Action. Once enquiries are completed the local authority should be notified and they should determine with the adult what, if any, further action is necessary and acceptable (14.94). In relation to the adult this should set out: • what steps are to be taken to assure the adult’s safety in the future • the provision of any support, treatment or therapy including on-going advocacy • any modifications needed in the way services are provided • how best to support the adult through any action they take to seek justice or redress • any ongoing risk management strategy as appropriate; and • any action to be taken in relation to the person or organisation that has caused the concern (14.95).
Sample 1
Taking Action. We will formally acknowledge and seek to investigate all reports misconduct. Where appropriate, we will provide advice and support and work with other agencies to bring about a satisfactory resolution. In instances where efforts at conciliation have failed, we will take the route of legal action. This may involve Court proceedings and termination of an Introductory Tenancy.
Sample 1Sample 2
Taking Action. The EU Commission’s Inquiry into the Pharmaceutical Sector Within this regulatory context, the pharmaceutical industry in Europe is characterised by a low rate of innovation and the delayed entry of generic producers.81 This has led the Commission to bring the pharmaceutical industry into the spotlight. At the outset, it sought to acquire the information necessary to identify the appropriate policy responses. To this end, in 2008 the Commission launched an inquiry into the pharmaceutical industry, which confirmed the existence of dangerous downward trends in entry and innovation. In response to these worrying trends, the Commission urged the Member States to speed 76 Directive 20/2001/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use [2001] OJ L121/34. See also D Delcourt, “Public Health and the Preservation of Economic Competi- tiveness: the European Supplementary Protection Certificate for Medicinal Products” (2009) 4 Journal of Intellectual Property Law C Practice 439, 440. 77 Art 10 of Directive 83/2001/EC of 6 November 2001 on the Community code relating to medicinal products for human use [2001] OJ L311. 78 Delcourt, supra n 76, 442. 79 These certificates were introduced by Regulation (EEC) 1768/1992 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products [1992] OJ L182, subsequently amended by Regulation (EC) 469/2009 of 6 May 2009 concerning the supple- mentary protection certificate for medicinal products [2009] OJ L152/1. 80 Ibid, Art 13(1). 81 N Kroes, “Commission Launches Sector Inquiry into Pharmaceuticals”, SPEECH 08/18 Brussels (16 January 2008) available at xxxx://xxxxxx.xx/rapid/press-release_SPEECH-08-18_ en.htm?locale=en (accessed on 2 November 2014). up the reimbursement procedures for generic producers and advocated the establishment of a unified EU patent system.82 It also committed to increasing the scrutiny of anticompetitive practices in this sector by monitoring PSAs and initiating investigations where appropriate.83 Through four monitoring reports between 2008 and 2013, the Commission shed some light on the opaque universe of patent settlements in Europe. The Commission divided the PSAs into three categories:84 • category A settlements allow a generic to freely enter the market and may or may...
Sample 1
Taking Action. From District Plan to District Inquiry for Systemic Learning
Sample 1
Taking Action. We continually strive to improve our services. If you feel that the services provided to you by us or the Professionals is inadequate, please inform us using the contact information given below.
Sample 1

Related to Taking Action

  • Closing Actions All deliveries, payments and other transactions and documents relating to the Closing shall be interdependent, and none shall be effective unless and until all are effective (except to the extent that the party entitled to the benefit thereof has waived satisfaction or performance thereof as a condition precedent to the Closing).

  • Pending Actions There is no action, suit, arbitration, unsatisfied order or judgment, government investigation or proceeding pending against Purchaser which, if adversely determined, could individually or in the aggregate materially interfere with the consummation of the transaction contemplated by this Agreement.

  • Post-Closing Actions The Lead Borrower agrees that it will, or will cause its relevant Subsidiaries to, complete each of the actions described on Schedule 9.13 as soon as commercially reasonable and by no later than the date set forth in Schedule 9.13 with respect to such action or such later date as the Administrative Agent may reasonably agree.

  • Pre-Closing Actions As promptly as practicable, each Warrantor shall: (a) use best efforts to take all actions required of such party and to do all other things reasonably necessary, proper or advisable to consummate the transactions contemplated under the Transaction Documents; (b) file or supply, or cause to be filed or supplied, all applications, notifications and information required to be filed or supplied by such Warrantor pursuant to Law in connection with the Transaction Documents and the issuance of the Subscription Shares pursuant hereto and the consummation of the other transactions contemplated under the Transaction Documents; (c) use reasonable best efforts to obtain, or cause to be obtained, all consents (including any consents required under any Contract) necessary to be obtained by such party in order to consummate the transactions contemplated pursuant to the Transaction Documents; and (d) coordinate and cooperate with the other Parties in exchanging such information and supplying such assistance as may be reasonably requested by the other Parties in connection with any filings and other actions to be made or taken in order to consummate the transactions contemplated pursuant to the Transaction Documents.

  • Taking of Necessary Action; Further Action If, at any time after the Effective Time, any further action is necessary or desirable to carry out the purposes of this Agreement and to vest the Surviving Corporation with full right, title and possession to all assets, property, rights, privileges, powers and franchises of the Company and Merger Sub, the officers and directors of the Company and Merger Sub are fully authorized in the name of their respective corporations or otherwise to take, and will take, all such lawful and necessary action, so long as such action is not inconsistent with this Agreement.

  • Taking of Necessary Action Each of the parties hereto agrees to use its reasonable best efforts promptly to take or cause to be taken all action and promptly to do or cause to be done all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective the Closing of the transactions contemplated by this Agreement. Without limiting the foregoing, the Investor and the Company (a) will use their reasonable best efforts to make all filings, including filings under the HSR Act, and obtain all other Regulatory Approvals necessary or, in the opinion of the Investor or the Company, advisable in order to permit the consummation of the transactions contemplated hereby and (b) will not take actions (including by making other acquisitions of or investments in any other Person) that could reasonably be expected to have the effect of delaying or hindering the Closing of the transactions contemplated hereby. Each party shall execute and deliver both before and after the Closing such further certificates, agreements and other documents and take such other actions as the other party may reasonably request to consummate or implement the transactions contemplated hereby or to evidence such events or matters.

  • No Pending Action Except as disclosed in the Registration Statement, there is no action, suit or proceeding pending, or, to the knowledge of the Company, threatened or contemplated before or by any arbitrator, court or other government body, domestic or foreign, against or affecting any Issuer Entity or any respective subsidiary thereof which is required to be disclosed in the Registration Statement (other than as disclosed therein), or which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect the properties or assets thereof or the consummation of the transactions contemplated by this Agreement. The aggregate of all pending legal or governmental proceedings to which any Issuer Entity or any respective subsidiary thereof is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect or materially adversely affect other properties or assets of any Issuer Entity or any respective subsidiary thereof.

  • Agreements; Action Except as set forth on Schedule 4.6 or as disclosed in any Exchange Act Filings:

  • No Pending Actions There are no actions, suits or proceedings pending or to the knowledge of the Company, threatened against the Company at law or in equity or before or by any Federal or state commission, regulatory body or administrative agency or other governmental body, domestic or foreign, which will have a material adverse effect on the business or property of the Company.

  • Regulatory Action (a) If Executive is removed and/or permanently prohibited from participating in the conduct of the Bank’s affairs by an order issued under Section 8(e)(4) or 8(g)(1) of the Federal Deposit Insurance Act (“FDIA”) (12 U.S.C. 1818(e)(4) and (g)(1)), all obligations of the Bank under this Agreement shall terminate, as of the effective date of such order.